Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

99969

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	General Practitioners
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether the procurement process operated by NHS England in relation to general practitioner practices allows for the track record of the bidders sufficiently to be taken into account in the procurement decision.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2184
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>NHS England is responsible for procurement in relation to general practitioner practices, as holders of the contract for General Practice. When procuring these services, NHS England must work within the Procurement, Patient Choice and Competition Regulations 2013, and make sure that they take fair and transparent decisions on the best provider to deliver those services for National Health Service patients.</p><p> </p><p> </p><p> </p><p>The factors used to evaluate bids, in each procurement process, including the consideration of references and track records, are determined on a case-by-case basis.</p><p> </p> answering member printed Earl Howe grouped question UIN HL2185 question first answered 27/10/2014 12:39:20 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

99970

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	General Practitioners
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government why the procurement process operated by NHS England in relation to general practitioner practices allows for references in respect of the bidders to be taken up rather than allowing for a review of their track record.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2185
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>NHS England is responsible for procurement in relation to general practitioner practices, as holders of the contract for General Practice. When procuring these services, NHS England must work within the Procurement, Patient Choice and Competition Regulations 2013, and make sure that they take fair and transparent decisions on the best provider to deliver those services for National Health Service patients.</p><p> </p><p> </p><p> </p><p>The factors used to evaluate bids, in each procurement process, including the consideration of references and track records, are determined on a case-by-case basis.</p><p> </p> answering member printed Earl Howe grouped question UIN HL2184 question first answered 27/10/2014 12:39:21 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

93397

registered interest
date	14/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Haemolytic Uraemic Syndrome
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by the Minister of State for Care and Support, Norman Lamb MP, on 26 June (HC Deb, 278W), what progress has been made by the National Institute for Health and Care Excellence’s evaluation committee in the evaluation of eculizumab to treat atypical haemolytic uraemic syndrome.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2063
answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) published draft highly specialised technologies guidance on eculizumab for the treatment of atypical haemolytic uraemic syndrome on 4 September. Stakeholders had until 25 September to comment on NICE’s draft recommendations and I understand that it currently expects to issue final guidance to the NHS in January 2015.</p><p> </p> answering member printed Earl Howe question first answered 22/10/2014 12:05:46 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

93398

registered interest
date	14/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Institute for Health and Care Excellence
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government when the National Institute for Health and Care Excellence will review its programme for evaluating highly specialised technologies.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2064
answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently following an interim methods guide for its highly specialised technologies programme. We understand that NICE expects to commence a review of its methods guide later this year. As part of this review, NICE plans to undertake a public consultation in 2015.</p><p> </p> answering member printed Earl Howe question first answered 22/10/2014 12:06:28 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

93399

registered interest
date	14/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is the nature of the relationship between Ministers, the Prescribed Specialised Services Advisory Group and NHS England in prescribing specialised services under the Health and Social Care Act 2012.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2065
answer	answer is ministerial correction date of answer 24/10/2014 answer text <p>The Secretary of State for Health, in his Annual Assessment of National Health Service England’s Annual Report for the last financial year (2013-14), has stated that “[NHS England] must […] ensure that spending controls are effective, particularly around specialised commissioning.” A copy of the Secretary of State’s Annual Assessment has been placed in the library.</p><p> </p><p> </p><p> </p><p>Section 3B(1)(d) of the National Health Service Act 2006, as amended by the Health and Social Care Act 2012, gives the Secretary of State the power to require the NHS Commissioning Board (known as NHS England) to commission prescribed services or facilities in relation to England by making regulations. Using this power, the Secretary of State may require NHS England to commission specialised services for people with rare or very rare conditions. Before deciding whether to make regulations, the Secretary of State must (a) obtain appropriate advice for that purpose and (b) consult NHS England. The Prescribed Specialised Services Advisory Group (PSSAG) is a Department of Health appointed expert committee which was established in 2013 to provide the Secretary of State with this advice. NHS England commissions all the services listed in Schedule 4 of The National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012.</p><p> </p><p> </p><p> </p><p>The scope of specialised services directly commissioned by NHS England is kept under review.</p><p> </p> answering member printed Earl Howe grouped question UIN HL2066 HL2067 question first answered 24/10/2014 11:31:33 answering member 2000 label Biography information for Earl Howe attachment 1 file name Annual_Assessment_of_NHSE.pdf title Annual Assesment of NHSE
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

93400

registered interest
date	14/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they plan to change the scope of specialised services directly commissioned by NHS England.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2066
answer	answer is ministerial correction date of answer 24/10/2014 answer text <p>The Secretary of State for Health, in his Annual Assessment of National Health Service England’s Annual Report for the last financial year (2013-14), has stated that “[NHS England] must […] ensure that spending controls are effective, particularly around specialised commissioning.” A copy of the Secretary of State’s Annual Assessment has been placed in the library.</p><p> </p><p> </p><p> </p><p>Section 3B(1)(d) of the National Health Service Act 2006, as amended by the Health and Social Care Act 2012, gives the Secretary of State the power to require the NHS Commissioning Board (known as NHS England) to commission prescribed services or facilities in relation to England by making regulations. Using this power, the Secretary of State may require NHS England to commission specialised services for people with rare or very rare conditions. Before deciding whether to make regulations, the Secretary of State must (a) obtain appropriate advice for that purpose and (b) consult NHS England. The Prescribed Specialised Services Advisory Group (PSSAG) is a Department of Health appointed expert committee which was established in 2013 to provide the Secretary of State with this advice. NHS England commissions all the services listed in Schedule 4 of The National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012.</p><p> </p><p> </p><p> </p><p>The scope of specialised services directly commissioned by NHS England is kept under review.</p><p> </p> answering member printed Earl Howe grouped question UIN HL2065 HL2067 question first answered 24/10/2014 11:31:34 answering member 2000 label Biography information for Earl Howe attachment 1 file name Annual_Assessment_of_NHSE.pdf title Annual Assesment of NHSE
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

93401

registered interest
date	14/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the commissioning of specialised services by NHS England.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2067
answer	answer is ministerial correction date of answer 24/10/2014 answer text <p>The Secretary of State for Health, in his Annual Assessment of National Health Service England’s Annual Report for the last financial year (2013-14), has stated that “[NHS England] must […] ensure that spending controls are effective, particularly around specialised commissioning.” A copy of the Secretary of State’s Annual Assessment has been placed in the library.</p><p> </p><p> </p><p> </p><p>Section 3B(1)(d) of the National Health Service Act 2006, as amended by the Health and Social Care Act 2012, gives the Secretary of State the power to require the NHS Commissioning Board (known as NHS England) to commission prescribed services or facilities in relation to England by making regulations. Using this power, the Secretary of State may require NHS England to commission specialised services for people with rare or very rare conditions. Before deciding whether to make regulations, the Secretary of State must (a) obtain appropriate advice for that purpose and (b) consult NHS England. The Prescribed Specialised Services Advisory Group (PSSAG) is a Department of Health appointed expert committee which was established in 2013 to provide the Secretary of State with this advice. NHS England commissions all the services listed in Schedule 4 of The National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012.</p><p> </p><p> </p><p> </p><p>The scope of specialised services directly commissioned by NHS England is kept under review.</p><p> </p> answering member printed Earl Howe grouped question UIN HL2065 HL2066 question first answered 24/10/2014 11:31:31 answering member 2000 label Biography information for Earl Howe attachment 1 file name Annual_Assessment_of_NHSE.pdf title Annual Assesment of NHSE
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

93402

registered interest
date	14/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what action they will take to ensure that NHS England ensures parity of esteem as required by the Health and Social Care Act 2012, the NHS Mandate for 2013 to 2015 and the Refreshed Mandate for 2014 to 2015.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2068
answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>The Government holds the National Health Service to account for achieving parity of esteem as required by the Health and Social Care Act 2012, through setting objectives in the NHS England Mandate for 2013-15 and the refreshed Mandate for 2014-15. In addition to measuring progress on specific objectives in the Mandate, outcomes for mental health patients are monitored through the NHS Outcomes Framework, which forms an essential part of the way in which the Secretary of State holds NHS England to account.</p><p> </p><p> </p><p> </p><p>Our recently published five-year plan,<em> Achieving Better Access to Mental Health Services by 2020,</em> sets out action the Government is taking to provide better access to mental health services within the next year, including the first ever national waiting time standards for mental health services. It also sets out our vision for further progress by 2020.</p><p> </p><p> </p><p> </p><p>£40 million in additional funding has been identified to enable change in the current financial year, and a further £80 million will be freed up for 2015-16 to support implementation of waiting times in mental health services.</p><p> </p> answering member printed Earl Howe question first answered 28/10/2014 15:13:50 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

92377

registered interest
date	06/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the impact of the new Pharmaceutical Price Regulation Scheme on small and medium-sized biopharmaceutical enterprises.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1939
answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) was agreed with the Association of the British Pharmaceutical Industry. It did not include the exemption from certain requirements for companies with health service sales of between £5 million and £25 million a year that were a feature of the 2009 PPRS. However companies with sales of health service medicines of less than £5 million a year (not counting global sales) are exempt from making any payments under the 2014 PPRS scheme.</p><p> </p><p> </p><p> </p><p>The PPRS benefits businesses making new medicines. A company that develops and brings a new medicine (new active substance) to the market from 1 January 2014, does not have to make PPRS payments to Government on the sales of these new medicines for the lifetime of the 2014 scheme. This particularly helps companies which only have new, innovative medicines in their portfolio.</p><p> </p><p> </p><p> </p><p>The Government remains committed to ensuring that the United Kingdom is a world leading place for life science research and investment through the Strategy for UK Life Sciences. The Department has assessed the impact of the PPRS and does not believe that there will be any significant impact on research and development investment in the UK.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1940 HL1941 question first answered 16/10/2014 14:45:20 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

92378

registered interest
date	06/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government why the protection afforded to small and medium-sized enterprises with sales between £5 million and £25 million under the previous Pharmaceutical Price Regulation Scheme has not been carried forward into the new scheme.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1940
answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) was agreed with the Association of the British Pharmaceutical Industry. It did not include the exemption from certain requirements for companies with health service sales of between £5 million and £25 million a year that were a feature of the 2009 PPRS. However companies with sales of health service medicines of less than £5 million a year (not counting global sales) are exempt from making any payments under the 2014 PPRS scheme.</p><p> </p><p> </p><p> </p><p>The PPRS benefits businesses making new medicines. A company that develops and brings a new medicine (new active substance) to the market from 1 January 2014, does not have to make PPRS payments to Government on the sales of these new medicines for the lifetime of the 2014 scheme. This particularly helps companies which only have new, innovative medicines in their portfolio.</p><p> </p><p> </p><p> </p><p>The Government remains committed to ensuring that the United Kingdom is a world leading place for life science research and investment through the Strategy for UK Life Sciences. The Department has assessed the impact of the PPRS and does not believe that there will be any significant impact on research and development investment in the UK.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1939 HL1941 question first answered 16/10/2014 14:45:21 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath